SCHEMBL3229901

SCHEMBL3229901

CCCn1c(=O)n(Cc2ccc(Cl)cc2)c(=O)c2c1nc(N1CCOCC1)n2C

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.69
SMN1; SMN2 Q16637 4/20 0.69
STAT6 P42226 2/20 0.69
MAPT P10636 2/20 0.67
HTT P42858 5/20 0.60
GAA P10253 1/20 0.60
ALDH1A1 P00352 2/20 0.58
KDM4E B2RXH2 1/20 0.58
ADRB2 P07550 1/20 0.58
HIF1A Q16665 1/20 0.58
ADORA3 P0DMS8 1/20 0.57
NPSR1 Q6W5P4 2/20 0.55
DPP4 P27487 1/20 0.55
HPGD P15428 1/20 0.52
TSHR P16473 1/20 0.52
KMT2A Q03164 1/20 0.52
MAOB P27338 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227456 0.91 LMNA (0.82) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL3235634 0.91 LMNA (0.78) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL3233379 0.90 LMNA (0.70) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL3233890 0.90 LMNA (0.80) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL3232809 0.88 LMNA (0.67) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL3237005 0.86 LMNA (0.65) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL3231786 0.82 LMNA (0.60) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL24554889 0.82 LMNA (0.79) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL24554898 0.81 LMNA (1.00) LMNASMN1; SMN2STAT6MAPTHTT
SCHEMBL24554867 0.80 LMNA (0.98) LMNASMN1; SMN2STAT6MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP claimed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US claimed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO claimed
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023704-A1 Novel Compounds 737 GRPR, GABRB1, GABBR1 LMNA 3908/4885SMN1; SMN2 983/4885STAT6 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.